Mangoceuticals, Inc.
MGRX
$4.76
-$0.52-9.85%
Weiss Ratings | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | -- | |||
Price History | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 13.20% | |||
30-Day Total Return | 59.20% | |||
60-Day Total Return | 90.40% | |||
90-Day Total Return | 96.69% | |||
Year to Date Total Return | 91.16% | |||
1-Year Total Return | 63.07% | |||
2-Year Total Return | -- | |||
3-Year Total Return | -- | |||
5-Year Total Return | -- | |||
52-Week High % Change | -68.57% | |||
52-Week Low % Change | 155.07% | |||
Price | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $16.80 | |||
52-Week Low Price | $2.07 | |||
52-Week Low Price (Date) | Dec 30, 2024 | |||
52-Week High Price (Date) | May 21, 2024 | |||
Valuation | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 13.52M | |||
Enterprise Value | 13.72M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -5.88 | |||
Earnings Per Share Growth | -26.79% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 14.08 | |||
Price/Book (Q) | 0.84 | |||
Enterprise Value/Revenue (TTM) | 18.17 | |||
Price | $4.76 | |||
Enterprise Value/EBITDA (TTM) | -1.81 | |||
Enterprise Value/EBIT | -1.81 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 2.01M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 214 242 9619 | |||
Address | 15110 North Dallas Parkway Dallas, TX 75248 | |||
Website | www.mangoceuticals.com | |||
Country | United States | |||
Year Founded | 2021 | |||
Profitability | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,005.07% | |||
Profit Margin | -1,235.04% | |||
Management Effectiveness | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -57.89% | |||
Return on Equity | -- | |||
Income Statement | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 755.10K | |||
Total Revenue (TTM) | 755.10K | |||
Revenue Per Share | $0.38 | |||
Gross Profit (TTM) | 442.50K | |||
EBITDA (TTM) | -7.57M | |||
EBIT (TTM) | -7.59M | |||
Net Income (TTM) | -9.33M | |||
Net Income Avl. to Common (TTM) | -9.33M | |||
Total Revenue Growth (Q YOY) | -45.60% | |||
Earnings Growth (Q YOY) | -11.13% | |||
EPS Diluted (TTM) | -5.88 | |||
EPS Diluted Growth (Q YOY) | 41.44% | |||
Balance Sheet | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 73.90K | |||
Cash Per Share (Q) | $0.04 | |||
Total Current Assets (Q) | 104.10K | |||
Total Preferred Equity (Q) | 0.00 | |||
Total Equity (Q) | 13.39M | |||
Current Ratio (Q) | 0.075 | |||
Book Value Per Share (Q) | $6.27 | |||
Total Assets (Q) | 14.79M | |||
Total Current Liabilities (Q) | 1.39M | |||
Total Debt (Q) | 269.00K | |||
Total Liabilities (Q) | 1.40M | |||
Total Common Equity (Q) | 13.39M | |||
Cash Flow | MGRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 65.00K | |||
Cash from Financing (TTM) | 4.21M | |||
Net Change in Cash (TTM) | -1.16M | |||
Levered Free Cash Flow (TTM) | -770.70K | |||
Cash from Operations (TTM) | -5.43M | |||